References
- 1. DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg’s cancer: Principles & practice of oncology. 10th ed., 2014, United States: Lippincott Williams and Wilkins, 1540.
- 2. Mentzel T, van den Berg E, Molenaar W. Myxofibrosarcoma. In: Fletcher C, Unni K, Mertens F. WHO classification of tumors - pathology and genetics, tumors of soft tissue and bone. 2002, Lyon: IARC Press, 102-1031.
- 3. Castro BAC, Piancastelli ACC, Meyer RLB, Piancastelli PM, Ribeiro CA, Miranda RMC. Myxofibrosarcoma - Case report. 2016; 91(1):97-9.
- 4. Dodd LG, Bui MM. Atlas of Soft Tissue and Bone Pathology: With Histologic, Cytologic, and Radiologic Correlations. 2015, New York: Demos Medical, 68-71.
- 5. Schepper AM, Vanhoenacker F, Gielen J, Parizel PM. Imaging of soft tissue tumors. 3. 2006, Berlin Heidelberg New York: Springer-Verlag, 196-198.
- 6. Mentzel T, Calonje E, Wadden C, Camplejohn RS, Beham A, Smith MA, Fletcher CD. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J SurgPathol. 1996; 20:391-405.
- 7. Merck C, Angervall L, Kindblom LG, Oden A. Myxofibrosarcoma. A malignant soft tissue tumor of fibroblastichistiocytic origin. A clinicopathologic and prognostic study of 110 cases using multivariate analysis. Acta PatholMicrobiol Immunol Scand. 1953; Suppl 282:1-40.
- 8. Weiss SW, Enzinger FM. Myxoid variant of malignant fibrous histiocytoma. Cancer. 1977; 39:1672-1685.
- 9. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997; 350:1647–54.
- 10. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. ClinOrthopRelat Res. 1980; 153:106-120.
- 11. Smolle MA, Dimosthenis A, Per-Ulf T, Szkandera J, Liegl-Atzwanger B, Leithner A. Diagnosis and treatment of soft-tissue sarcomas of the extremities and trunk. EFORT Open Rev. 2017; 2:421-431.
- 12. The ESMO/ European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2014; 25:iii102-iii112.
- 13. Judson I, Verweij J, Gelderblom H et al. European Organisation and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupDoxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 2014; 15:415-423.10.1016/S1470-2045(14)70063-4
- 14. Antman K, Crowley J, Balcerzak SP et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J ClinOncol. 1993; 11:1276-1285.